This topic is empty. Viewing 0 reply threads Author Posts February 17, 2020 at 12:01 pm #19215 Marta RibeiroKeymaster Overall, first-line use of Genentech’s Ocrevus for MS patients has remained stable through 2019 compared to 2018, according to Spherix Global Insights. Read more here. What do you think of this information? Author Posts Viewing 0 reply threads You must be logged in to reply to this topic. Log In Username: Password: Keep me signed in Log In